Over the past 30 years, the focus of peritoneal dialysis research has changed from the technical issues related to the establishment of clinical peritoneal dialysis to complex problems of peritoneal membrane biology. Here, we present how these research topics developed, discuss their significance for clinical science, and outline future challenges for peritoneal dialysis research.
DuweA.K., VasS.I., WeatherheadJ.W.Effects of the composition of peritoneal dialysis fluid on chemiluminescence, phagocytosis, and bactericidal activity in vitro.Infect Immun1981; 33: 130–5.
2.
StylianouE., JennerL.A., DaviesM., ColesG.A., WilliamsJ.D.Isolation, culture and characterization of human peritoneal mesothelial cells.Kidney Int1990; 37: 1563–70.
3.
JörresA., LudatK., LangJ., SanderK., GahlG.M., FreiU.Establishment and functional characterization of human peritoneal fibroblasts in culture: Regulation of interleukin-6 production by proinflammatory cytokines.J Am Soc Nephrol1996; 7: 2192–201.
4.
TopleyN., WilliamsJ.D.Role of the peritoneal membrane in the control of inflammation in the peritoneal cavity.Kidney Int Suppl1994; 48: S71–8.
5.
WitowskiJ., TopleyN., JörresA., LiberekT., ColesG.A., WilliamsJ.D.Effect of lactate-buffered peritoneal dialysis fluids on human peritoneal mesothelial cell interleukin-6 and prostaglandin synthesis.Kidney Int1995; 47: 282–93.
6.
JörresA., WilliamsJ.D., TopleyN.Peritoneal dialysis solution biocompatibility: Inhibitory mechanisms and recent studies with bicarbonate-buffered solutions.Perit Dial Int1997; 17(Suppl 2): S42–6.
7.
WilliamsJ.D., CraigK.J., TopleyN., Von RuhlandC., FallonM., NewmanG.R.Morphologic changes in the peritoneal membrane of patients with renal disease.J Am Soc Nephrol2002; 13: 470–9.
8.
Yanez-MoM., Lara-PezziE., SelgasR., Ramirez-HuescaM., Dominguez-JimenezC., Jimenez-HeffernanJ.A.Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells.N Engl J Med2003; 348: 403–13.
9.
WieslanderA.P., NordinM.K., KjellstrandP.T., BobergU.C.Toxicity of peritoneal dialysis fluids on cultured fibroblasts, L-929.Kidney Int1991; 40: 77–9.
10.
WitowskiJ., WisniewskaJ., KorybalskaK., BenderT.O., BreborowiczA., GahlG.M.Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells.J Am Soc Nephrol2001; 12: 2434–41.
11.
MactierR.A., SprosenT.S., GokalR., WilliamsP.F., LindberghM., NaikR.B.Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain.Kidney Int1998; 53: 1061–7.
12.
RippeB., SimonsenO., HeimburgerO., ChristenssonA., HaraldssonB., StelinG.Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products.Kidney Int2001; 59: 348–57.
13.
ZeierM., SchwengerV., DeppischR., HaugU., WeigelK., BahnerU.Glucose degradation products in PD fluids: Do they disappear from the peritoneal cavity and enter the systemic circulation?Kidney Int2003; 63: 298–305.
14.
WilliamsJ.D., TopleyN., CraigK.J., MackenzieR.K., PischetsriederM., LageC.The Euro-Balance Trial: The effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane.Kidney Int2004; 66: 408–18.
15.
MackenzieR.K., HolmesC.J., MoseleyA., JenkinsJ.P., WilliamsJ.D., ColesG.A.Bicarbonate/lactate- and bicarbonate-buffered peritoneal dialysis fluids improve ex vivo peritoneal macrophage TNFalpha secretion.J Am Soc Nephrol1998; 9: 1499–506.
16.
WitowskiJ., KorybalskaK., KsiazekK., Wisniewska-ElnurJ., JörresA., LageC.Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells.Nephrol Dial Transplant2004; 19: 917–24.
